Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 in advanced solid tumors with IDH1 mutation
NCT02073994Phase 1Completed
- Sponsor
- Servier
- Start
- Mar 2014
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ivosidenib in solid tumor, glioma, cholangiocarcinoma (CCA) and 1 more, sponsored by Servier. Primary endpoints: Incidence of Adverse Events at 26 weeks and Maximum Tolerated Dose and/or Recommended Phase II Dose at 26 weeks. Started Mar 2014; status: completed.
02
Drugs
ivosidenib
03
Conditions
solid tumorgliomacholangiocarcinoma (CCA)chondrosarcoma
Beyond the preview
Go deeper on NCT02073994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02073994.